VAV1 is altered in 0.83% of all cancers with diffuse large B-cell lymphoma, not otherwise specified, follicular lymphoma, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified, and B-cell lymphoblastic leukemia/lymphoma having the greatest prevalence of alterations .
The most common alterations in VAV1 are VAV1 Loss (0.33%), VAV1 Amplification (0.14%), VAV1 E740* (0.05%), VAV1 A513T (0.02%), and VAV1 D161E (0.02%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.